New drug shows promise for Long-Term control of chronic hives
NCT ID NCT06736262
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing the long-term safety and effectiveness of a drug called briquilimab for people with chronic hives. It includes 67 participants who have already completed a previous trial with the same drug. The goal is to see if briquilimab remains safe and helps control hives over a longer period.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
briquilimab
What this could lead to
If successful, this could point toward a new long-term treatment option for chronic hives, reducing symptoms and improving quality of life.
What could go wrong
This is an early-phase extension study with only 67 participants, so results may not apply to everyone. Long-term safety and effectiveness are still uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigative Site 101
Baltimore, Maryland, 21224, United States
-
Investigative Site 103
Cincinnati, Ohio, 45236, United States
-
Investigative Site 105
San Diego, California, 92123, United States
-
Investigative Site 108
Little Rock, Arkansas, 72205, United States
-
Investigative Site 109
Boise, Idaho, 83706, United States
-
Investigative Site 110
Indianapolis, Indiana, 46250, United States
-
Investigative Site 111
Murray, Utah, 84107, United States
-
Investigative Site 115
Seattle, Washington, 98101, United States
-
Investigative Site 116
Tampa, Florida, 33613, United States
-
Investigative Site 118
Birmingham, Alabama, 35244, United States
-
Investigative Site 121
White Marsh, Maryland, 21162, United States
-
Investigative Site 123
Lafayette, Louisiana, 70508, United States
-
Investigative Site 124
Normal, Illinois, 61761, United States
-
Investigative Site 201
Berlin, 12203, Germany
-
Investigative Site 202
Marburg, Hesse, 35043, Germany
-
Investigative Site 204
Münster, North Rhine-Westphalia, 48149, Germany
-
Investigative Site 206
Lübeck, Schleswig-Holstein, 23538, Germany
-
Investigative Site 209
Dresden, Saxony, 01307, Germany
-
Investigative Site 210
München, Bavaria, 80802, Germany